RADIOPHARMACEUTICALS: DIAGNOSIS AND TREATMENT OF CANCER

放射性药物可以诊断和治疗癌症。最近的 特异性单抗发展的爆炸性进展 针对个别癌症的研究极大地拓宽了视野 放射性药物。然而，我们才刚刚开始探索 这些放射性药物的临床应用。一个主要原因是 放射性标记化合物只是缓慢地达到临床用途 在它们的发展过程中有多个连续的步骤 每一步都需要专业科学家的专业知识。这 这一过程代价高昂，而且难以协调。很少有学者 组织拥有广泛的专业知识来开展此类工作 风险企业和制药公司可能只会看到有限的 针对特定目标的单一放射性药物的市场 癌症。事实上，这样的放射性药物成了“孤儿” 药物“，具有很大的临床价值，但太昂贵，无法吸引 “家长”。我们提出了一个计划项目，将使 有用放射性标记化合物的有序开发 通过临床试验诊断和生产的概念和产品 癌症的治疗。 该计划项目将把科学家组织成核心， 严刑拷问将确保一个有前途的特工有效地 从合成到放射性药物再到临床 评估。该计划项目将支持 放射性药物开发核心设施由1) 生产和标识；2)临床前评估；3)剂量学； 4)临床评价；5)管理核心。每个核心都将 由拥有足够时间和知识的科学家组成 进行专门而协调的实验，每个核心都将 有足够的空间、设备和资金来支持 这些科学家。他们的努力将由校长协调 调查员和行政委员会以确保有效性 在项目资助计划中。 由以下项目支持的跨学科、协同子项目 设施包括对开发的放射性药物进行评估 来源：用于诊断的单抗和可能的 治疗：淋巴瘤、膀胱癌、乳腺癌以及 去甲肾上腺素的类似物间十二烷基苄基胍的诊断 治疗神经母细胞瘤。这些放射性药物将是 在动物身上更好地评估通过开发一种高- 分辨率小动物断层成像仪。通过这件事 核心实验室支持的一系列相辅相成的项目， 最终的结果应该是改进诊断和治疗 癌症。

Radiopharmaceuticals can diagnose and treat cancer. The recent explosion in development of monoclonal antibodies specifically directed at individual cancers has greatly broadened the horizons of radiopharmaceuticals. Yet we have only begun to explore these clinical uses of radiopharmaceuticals. A major reason that radiolabeled compounds have only slowly reached clinical utility is that there are multiple sequential steps in their development with each step requiring the expertise of specialized scientists. This process is expensive and difficult to coordinate. Few academic organizations have the broad-ranging expertise to undertake such ventures, and pharmaceutical companies may see but a limited market for a single radiopharmaceutical directed at a particular cancer. Indeed, such radiopharmaceuticals become "orphan drugs", agents of great clinical value but too costly to attract a "parent". We propose a program project that will enable the orderly development of useful radiolabeled compounds from concept and production through clinical trials in the diagnosis and treatment of cancers. The program project will organize scientists into cores where collaberations will ensure that a promising agent will efficiently proceed from synthesis to radiopharmaceutical to clinical evaluation. The program project will support a radiopharmaceutical development core facility composed of 1) production and labeling; 2) pre-clinical evaluation; 3) dosimetry; 4) clinical evaluation; and 5) administrative cores. Each core will consist of scientists with sufficient time and knowledge to carry out specialized yet coordinated experiments, and each core will have the space, equipment and funds to support the efforts of these scientists. Their efforts will be coordinated by the principal investigator and an administrative committee to ensure efficacy in the program project grant. Interdisciplinary, synergistic sub-projects supported by the facility include the evaluation of radiopharmaceuticals developed from: monoclonal antibodies for the diagnosis and possible therapy of: lymphoma, bladder and breast cancers as well as metaiodobenzylguanidine an analog of norepinephrine to diagnose and treat neuroblastomas. These radiopharmaceuticals will be better evaluated in animals through the development of a high- resolution small animal tomographic imaging device. Through this series of mutually reinforcing projects supported by the core labs, the end result should be improved diagnosis and treatment of cancer.